TWD 56.5
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -85.5 Million TWD | -1.21% |
2022 | -84.48 Million TWD | -2.15% |
2021 | -82.69 Million TWD | 3.63% |
2020 | -85.81 Million TWD | 42.46% |
2019 | -161.91 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -33.18 Million TWD | -3.39% |
2024 Q2 | 5.11 Million TWD | 111.81% |
2023 Q4 | -32.25 Million TWD | -118.34% |
2023 FY | - TWD | -1.21% |
2023 Q3 | -14.77 Million TWD | -152.31% |
2023 Q2 | -5.85 Million TWD | 82.05% |
2023 Q1 | -32.61 Million TWD | -19.79% |
2022 Q4 | -27.23 Million TWD | 0.0% |
2022 FY | - TWD | -2.15% |
2021 FY | - TWD | 3.63% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Allied Biotech Corporation | 204.79 Million TWD | 141.75% |
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | 136.998% |
TTY Biopharm Company Limited | 1.52 Billion TWD | 105.609% |
Synmosa Biopharma Corporation | 1 Billion TWD | 108.476% |
Orient EuroPharma Co., Ltd. | 582.93 Million TWD | 114.667% |
Center Laboratories, Inc. | -175.17 Million TWD | 51.19% |
Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | 375.383% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | 149.596% |
InnoPharmax Inc. | -62.12 Million TWD | -37.638% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | 167.495% |
Excelsior Biopharma Inc. | -29.36 Million TWD | -191.127% |
DV Biomed Co., Ltd. | 407.64 Million TWD | 120.975% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 90.627% |
Handa Pharmaceuticals, Inc. | 802.78 Million TWD | 110.651% |
UniPharma Co., Ltd. | -16.25 Million TWD | -426.031% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | 165.114% |
Alar Pharmaceuticals Inc. | 394.52 Million TWD | 121.672% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | 137.447% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | -119.042% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | 804.582% |
TSH Biopharm Corporation Limited | 99.35 Million TWD | 186.06% |